Michael Wilson is a Neurology physician.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1500 Owens St
Suite 320
San Francisco, CA 941582334
Telephone
414-353-2069Registry record last updated 3 Sept 2013.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- VERTEX PHARMACEUTICALS INCORPORATEDProgram year20251 payment
- Takeda Pharmaceuticals U.S.A., Inc.Program year20211 payment
- Genentech, Inc.Program year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Musculoskeletal
58.5%gamma-Aminobutyric Acid-ergic Agonist58.5%Baclofen100%Part D≥14 patientsCancer & immunology
26.8%Other immunosuppressants26.8%Dimethyl Fumarate50%Vumerity50%Part D<11 patientsNervous system
14.6%Central Nervous System Stimulant14.6%Methylphenidate Er100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
9 NIH research awards on record, funded 1985–2026 per NIH RePORTER. The latest:
- Antigen-directed therapies for autoantibody associated neuroinflammatory diseases.
University of California, San Francisco
FY2026$2,098,085RM1NS138808 - Autoimmune Encephalitis and Psychiatric Morbidity: Identifying and Characterizing Novel Antibody Targets
University of California, San Francisco
FY2026$816,760R01MH122471 - Antigen-directed therapies for autoantibody associated neuroinflammatory diseases.
University of California, San Francisco
FY2025$2,098,085RM1NS138808
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Bruce Miller, MD
University of California, San Francisco (UCSF)
Bradley Boeve, MD
Mayo Clinic
Richard Lipton, MD
Albert Einstein College of Medicine
Steven Dekosky, MD
University of Florida Health
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”